Progress on mRNA tumor vaccine with non-viral delivery system
10.12206/j.issn.2097-2024.202410034
- VernacularTitle:mRNA肿瘤疫苗非病毒递送系统研究进展
- Author:
Jiao ZHOU
1
;
Jianyu ZHENG
1
;
Sizhen WANG
1
;
Feng YANG
1
Author Information
1. School of Pharmacy, Naval Medical University, Shanghai 200433, China.
- Publication Type:Reviews
- Keywords:
non-viral vectors;
mRNA vaccine;
tumor vaccine;
immunotherapy
- From:
Journal of Pharmaceutical Practice and Service
2025;43(3):109-116
- CountryChina
- Language:Chinese
-
Abstract:
At the end of 2020, the FDA issued emergency use authorization for two mRNA vaccines（BNT162b2 and mRNA-1273）, which had provided important support in the response to the COVID-19 pandemic. The great success of these COVID-19 vaccines based on non-viral vectors has promoted the research and application of mRNA vaccines in the treatment of diseases such as tumors. Compared with virus-based delivery systems, non-viral carriers have significant advantages in biological safety and versatility. Therefore, non-viral vectors have become a research hotshot for mRNA tumor vaccines. In this paper, the latest research progress on lipid nanoparticles, polymers, peptides and inorganic materials were introduced. In addition, recent clinical trials of mRNA tumor vaccines were reviewed and the challenges and prospects of non-viral vectors in clinical transformation of mRNA tumor vaccines were discussed.
